Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Uncovers Prostate-Specific Proteins

NEW YORK, Feb. 14 - Compugen researchers have discovered two previously unknown prostate-specific proteins, the company said on Wednesday.


The proteins were first predicted by Compugen's computational biology platform, then verified through molecular biology techniques in the corporate labs.


The proteins are encoded by alternative mRNA splice variants of KlK3 and KLK2, genes that produce prostate specific antigen and human kallikrein 2 (hK2). Both PSA and hK2 are secreted in the human prostate and have been used as biomarkers for prostate cancer.


The newly discovered splice variant products are apparently unrelated to other proteins in the kallikrein family, but their expression, regulation, and secretion is similar to PSA. That finding suggests that these new proteins may prove to be useful in understanding the biology of prostate cancer, and suggest new drug targets or diagnostic markers.


The finding is published in The Journal of Biological Chemistry.


The LEADS bioinformatics platform incorporates genomics and proteomics tools and information from public and private databases to generate predictions of genes, mRNA transcripts, splice variants, and proteins.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more